Personalized cancer vaccine succeeds in key trial

A personalized cancer vaccine developed by Merck and Moderna has shown positive results in its first phase 3 clinical trial. The experimental mRNA treatment is designed to target an individual's specific cancer and is being tested in combination with an immunotherapy drug from Merck. Moderna's stock rose sharply following the joint announcement of the trial results.